Preclinical animal models of multiple myeloma

dc.contributor.authorLwin, Sein T.
dc.contributor.authorEdwards, Claire M.
dc.contributor.authorSilbermann, Rebecca
dc.contributor.departmentDepartment of Medicine, IU School of Medicineen_US
dc.date.accessioned2017-06-21T14:15:17Z
dc.date.available2017-06-21T14:15:17Z
dc.date.issued2016-02
dc.description.abstractMultiple myeloma is an incurable plasma-cell malignancy characterized by osteolytic bone disease and immunosuppression. Murine models of multiple myeloma and myeloma bone disease are critical tools for an improved understanding of the pathogenesis of the disease and the development of novel therapeutic strategies. This review will cover commonly used immunocompetent and xenograft models of myeloma, describing the advantages and disadvantages of each model system. In addition, this review provides detailed protocols for establishing systemic and local models of myeloma using both murine and human myeloma cell lines.en_US
dc.identifier.citationLwin, S. T., Edwards, C. M., & Silbermann, R. (2016). Preclinical animal models of multiple myeloma. BoneKEy Reports, 5, 772. http://doi.org/10.1038/bonekey.2015.142en_US
dc.identifier.urihttps://hdl.handle.net/1805/13130
dc.language.isoen_USen_US
dc.publisherSpringerNatureen_US
dc.relation.isversionof10.1038/bonekey.2015.142en_US
dc.relation.journalBoneKEy Reportsen_US
dc.rightsPublisher Policyen_US
dc.sourcePMCen_US
dc.subjectMultiple myelomaen_US
dc.subjectPlasma-cell malignanciesen_US
dc.subjectOsteolytic bone diseaseen_US
dc.subjectImmunosuppressionen_US
dc.subjectMyeloma bone diseaseen_US
dc.titlePreclinical animal models of multiple myelomaen_US
dc.typeArticleen_US
ul.alternative.fulltexthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747080/en_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
bonekey2015142.pdf
Size:
460.69 KB
Format:
Adobe Portable Document Format
Description:
Laboratory Methods
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.88 KB
Format:
Item-specific license agreed upon to submission
Description: